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Objective. To assess the main clinical, radiographic, and histopathologic features of patients with bisphosphonate-induced
osteonecrosis of the jaws (BIONJ).
Study Design. Patients with BIONJ diagnosed and treated at the Head and Neck Department, Instituto Nacional de
Cancerologı´a, Bogota´, DC, Colombia, between January 2012 and February 2014 were retrospectively included. Patients
treated with sequestrectomy or curettage were excluded. Specimens from selected patients were reexamined under a light
microscope. Clinical and imaging findings and sociodemographic variables were also reviewed.
Results. Five stage 3 BIONJ cases were included. Imaging found massive osteolysis. Histopathology found devitalized
trabecular bone, an absence of osteoblastic rimming, osteoclastic necrosis, and viable periosteum. Actinomyces spp colonies
were limited to superficial layers.
Conclusions. BIONJ histopathology is different from that of other necrotizing and inflammatory bone diseases. This relates to
the known antiresorptive mechanism of bisphosphonates, which is the basis of their therapeutic action. Nevertheless, further
study with larger series should be accomplished. (Oral Surg Oral Med Oral Pathol Oral Radiol 2014;118:408-417)Bisphosphonates have been used for 2 decades to treat
patients with osteoporosis and to control malignancies
that compromise bone integrity.1 The clinical beneﬁt of
bisphosphonates is a result of their ability to decrease
bone turnover via the inhibition of osteoclastic pro-
cesses. Scientiﬁc evidence has conﬁrmed an increased
risk of developing osteonecrosis of the jaws in patients
treated with this group of drugs.1,2
Despite the clinical criteria established by the
American Association of Oral and Maxillofacial Sur-
geons (AAOMS) in 2007,3 bisphosphonate-induced
osteonecrosis of the jaws (BIONJ) may be confused
clinically with other conditions, such as osteor-
adionecrosis and osteomyelitis, owing to similar
symptoms and radiographic ﬁndings.4 Speciﬁcity is
conferred by the use of bisphosphonate therapy in theThis study was presented as a poster in the bisphosphonates category
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Open access under CC BY-NC-ND license.medical history. Therefore, it becomes essential to
assess the histopathologic features of BIONJ.
A few authors have assessed the histologic ﬁndings
of BIONJ, and the following histopathologic features
have been described: numerous bacterial colonies,
acellular necrotic bone, osteolysis, and massive inﬂam-
matory inﬁltration.5-8 However, there is scarce docu-
mentation that correlates current theories concerning the
mechanism and histopathologic features of BIONJ.
The purpose of this study was to assess the histo-
pathologic features of specimens obtained from patients
diagnosed with BIONJ, identifying the main clinical
and radiographic ﬁndings.
MATERIALS AND METHODS
Charts of patients diagnosed with BIONJ and treated at
the Head and Neck Department, Instituto Nacional de
Cancerología, Bogotá, DC, Colombia, between January
2012 and February 2014 were retrospectively included.
The BIONJ diagnosis was established according to the
AAOMS Task Force deﬁnition of BIONJ.3 The case
deﬁnition is as follows: the presence of nonhealing
exposed necrotic bone in the maxillofacial region thatStatement of Clinical Relevance
This series included patients diagnosed with
bisphosphonate-induced osteonecrosis of the jaws
treated by block resection. The histopathologic fea-
tures described herein may explain the physiopa-
thology of this disease, which is different from other
necrotizing and inﬂammatory conditions such as
osteoradionecrosis and suppurative osteomyelitis.
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Volume 118, Number 4 Franco-Pretto et al. 409has persisted for more than 8 weeks in a patient who
has received a systemic bisphosphonate but has no
history of radiation therapy of the jaws.
Patients treated with sequestrectomy or curettage
were excluded. Patients treated by block resection were
included so as to perform a comprehensive analysis of
the histopathologic features and overall structures
involved in BIONJ. Each specimen was reexamined
under a light microscope at  10,  40, and  100
magniﬁcation. The clinical, radiologic, and socio-
demographic data were obtained from charts of patients
included in the study and were tabulated. No institu-
tional review board approval was necessary to perform
this retrospective study. The authors have read the
Helsinki Declaration and have followed the guidelines
in this investigation.
RESULTS
A total of 5 patients satisﬁed the inclusion criteria; 4
were men and 1 was a woman. Age ranged from 55 to
78 years, with the average being 66.5 (SD  11.5).
Four patients were classiﬁed as having AAOMS BIONJ
stage 3 and one as having stage 2 at the time of
consultation. The clinicopathologic features of all 3
cases are summarized in Table I.op
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A 57-year-old man was diagnosed in January 2009 with
prostate cancer. Medical treatment included intravenous
4 mg of monthly zoledronic acid and 2.5 mg of daily oral
ibandronate, both for 3 years. After 30 doses of zole-
dronic acid, his dentist removed the left mandibular
second premolar because of chronic periodontitis. By
December 2011, the patient presented to his dentist with
swelling and painful exposed bone in the extraction area.
The patient was initially prescribed clindamycin, 300 mg
3 times daily; however, after 2 weeks of no response this
was changed to azithromycin, which also failed to con-
trol the apparent infection. By January 2012, the patient
was submitted by his dentist to the Head and Neck
Department. The initial examination found left mandib-
ular bone exposure with orocutaneous ﬁstulas in the third
quadrant of the oral cavity. Imaging ﬁndings included
evidence of stage 3 BIONJ (Figure 1, A). The histopa-
thology ﬁndings included bone necrosis with devitalized
trabecular bone, empty lacunae, and osteoclastic necrosis
without inﬂammatory inﬁltrate or metastasis (see
Figure 1, B-E). The patient was treated by partial hemi-
mandibulectomy without immediate reconstruction.T
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A 61-year-old man was diagnosed with multiple
myeloma in May 2011. He was treated by the oncology
department with 10-cycle chemotherapy (cisplatin,
Fig. 1. A, Radiolucent diffuse image with osteolytic pattern in left mandibular body compromising basal mandibular region. B,
Partial bone necrosis with empty lacunae and apoptotic detached 4-nuclei osteoclast (arrow) (hematoxylin-eosin, original
magniﬁcation  40). C, Trabecular bone layer in proximity to the oral cavity heavily inﬂuenced by the presence of an inﬂammatory
inﬁltrate, including numerous neutrophils (arrow) (hematoxylin-eosin, original magniﬁcation  100). D, Necrotic trabecular bone
with empty osteocytic lacunae (short arrows) and detached osteoclast (long arrow) (hematoxylin-eosin, original
magniﬁcation  40). E, Trabecular bone layer in proximity to the marrow space devoid of inﬂammatory cells with empty
osteocytic lacunae (arrows) (hematoxylin-eosin, original magniﬁcation  40).
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410 Franco-Pretto et al. October 2014etoposide) along with dexamethasone and zoledronic
acid, 4 mg intravenously, on a monthly schedule for
1 year. By June 2012, after 12 doses of zoledronic acid,
he presented to the Head and Neck Department with
pain and swelling over the left maxilla. His left
maxillary alveolar process was exposed, and a slight
suppurative exudate arose from the exposed bone.
There was no evidence of oronasal or oroantral ﬁstulas.
The patient was initially treated by curettage and oral
clindamycin (300 mg 4 times daily) without success.
Three months after his referral, the area of bone expo-
sure continued to enlarge and then developed drainage.
The patient was treated by left hemimaxillectomy
and ﬁbula ﬂap reconstruction. Tomographic imaging
conﬁrmed the clinical ﬁndings (Figure 2, A).Histopathologic ﬁndings included extended bone ne-
crosis with devitalized bone trabeculae and empty
lacunae without inﬂammatory inﬁltrate (see Figure 2,
B-F). The superﬁcial zones of the specimen contained
plasmocytes with positive reactivity to CD38 and
multiple myeloma oncogene 1 (MUM1), which is
compatible with plasmatic cell neoplasia (see Figure 2,
G-I). The clinical picture was compatible with BIONJ
stage 3.
Case 3
A 74-year-old man presented with a history of moder-
ately differentiated prostatic adenocarcinoma metastatic
to bone diagnosed in August 2009. He was treated
with chemotherapeutic management that included
Fig. 2. A, Axial computed tomography scans with bone window settings reveal the destruction of the alveolar bone process of the
left maxilla. B, Outermost layer of the specimen, revealing an area of periosteal bone formation (arrows) (hematoxylin-eosin,
original magniﬁcation  100). C, Surface colony of Actinomyces spp is seen (long arrows) along with devitalized trabecular bone
OOOO ORIGINAL ARTICLE
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412 Franco-Pretto et al. October 2014intravenous zoledronic acid, 4 mg monthly for 2 years,
and oral prednisone, 5 mg daily. After 21 doses of
zoledronic acid, his dentist removed the mesial root of
the left mandibular second molar because of chronic
periodontitis. After 3 months of a nonhealed socket
after extraction, he presented to the Head and Neck
Department with bone exposure and infection of the
mandibular left body with orocutaneous ﬁstula
(Figure 3, A, B). A panoramic image found an osteo-
lytic radiolucent process localized in the left mandibular
alveolar region (see Figure 3, C). The clinical picture
was compatible with BIONJ stage 3. The patient was
treated with partial left hemimandibulectomy without
reconstruction.
The histopathologic ﬁndings included a combination
of zones of bone necrosis with devitalized trabecular
bone and empty lacunae and necrotic osteoclasts with
evidence of apoptosis without inﬂammatory inﬁltrate
(see Figure 3, D, E). In other areas of the specimen,
surface colonies of Actinomyces spp were found (see
Figure 3, F, G).Case 4
A 55-year-old woman was diagnosed in December
2011 with breast cancer metastatic to bone. Medical
treatment included intravenous 4 mg of monthly
zoledronic acid and 2.5 mg of daily oral ibandronate,
both for 2 years. After 24 doses of zoledronic acid, her
dentist removed the right maxillary third molar
because of chronic periodontitis. By February 2013,
the patient presented to her dentist with swelling and
painful exposed bone in the extraction area. The pa-
tient was initially treated by normal saline solution
irrigation, followed by alveoloplasty. Her dentist did
not prescribe any antibiotic treatment. By May 2013,
the patient was submitted to the Head and Neck
Department. Intraoral examination found right maxil-
lary bone exposure with oroantral ﬁstulas in the
extraction area and suppurative exudate that arose
from the exposed bone (Figure 4, A). Surgical treat-
ment included right partial posterior hemi-
maxillectomy. Imaging ﬁndings included evidence of
stage 3 BIONJ (see Figure 4, B). The histopathologicwith empty osteocytic lacunae (short arrows) (hematoxylin-eosin, or
empty osteocytic lacunae (arrows) (hematoxylin-eosin, original mag
without inﬂammatory cells or ﬁbrosis. Extensive scalloping of bon
(hematoxylin-eosin, original magniﬁcation  40). F, Marrow space
cellular products along with empty osteocytic lacunae (short arrow),
varying extension and depth (long arrows). Absence of osteob
magniﬁcation  100). G, Mononuclear and multinucleated neopla
(arrows) (hematoxylin-eosin, original magniﬁcation  100). H, Nuc
myeloma oncogene 1 (MUM1) protein conﬁrming differentiated n
CD38þ (arrows), which conﬁrms the multiple myeloma diagnosis (ﬁndings included bone necrosis with devitalized
trabecular bone and empty lacunae without inﬂam-
matory inﬁltrate or metastasis (see Figure 4, C, D).Case 5
A 78-year-old man presented with a history of prostate
cancer metastatic to bone diagnosed in January 2012.
The patient was scheduled for removal of the inferior
incisors because of chronic periodontitis, and an infe-
rior denture was placed by his dentist 4 weeks before
starting medical treatment. He was treated with
chemotherapeutic management that included intrave-
nous zoledronic acid, 4 mg monthly for 2 years. After
20 doses of zoledronic acid, the patient developed
painful zones of spicule-like exposed bone in the
anterior mandibular region. His dentist removed the
exposed bone spicules and prescribed 0.12% chlor-
hexidine oral rinses 3 times daily. By January 2014, the
patient was submitted by his dentist to the Head and
Neck Department. He presented with infected, painful,
and exposed alveolar bone limited to the anterior
mandibular region. A panoramic image found general-
ized sclerotic changes compromising the lamina dura
(Figure 5, A).
The clinical picture was compatible with BIONJ
stage 2 at this time. The patient was initially treated by
removing the mobile segments of bony sequestrum,
along with doxycycline, 100 mg once daily, without
success. By February 2014, the area of bone exposure
continued to enlarge and then developed extraoral
drainage. The patient was reclassiﬁed then as BIONJ
stage 3 and treated by segmental resection of the
anterior mandibular alveolar process. The histopatho-
logic ﬁndings included a combination of zones of bone
necrosis with devitalized trabecular bone and empty
lacunae (see Figure 5, B). In other areas of the spec-
imen, surface colonies of Actinomyces spp were found
(see Figure 5, C).DISCUSSION
The clinical and imaging aspects in this case series are
consistent with those previously described in theiginal magniﬁcation  40). D, Devitalized lamellar bone with
niﬁcation  40). E, Necrotic bone and empty marrow spaces,
e edges suggestive of interrupted Howship lacunae (arrows)
is seen to be acellular and devoid of extracellular collagen or
scalloped bone edges representing empty Howship lacunae of
lastic rimming is also noted (hematoxylin-eosin, original
stic plasma cells with prominent nucleoli with little stroma
lear and cytoplasmic positivity of tumor cells for the multiple
eoplastic plasma cells (MUM1,  100). I, Tumor cells are
CD38,  100).
Fig. 3. A, Mandibular alveolar bone exposed with infection signs. B, Extraoral left submandibular ﬁstulas (arrow). C, Pano-
ramic image reveals radiolucent osteolytic image bone mesial to inferior left third molar. D, Marrow space is seen to be
acellular and devoid of extracellular collagen or cellular products, extended bone necrosis without inﬂammatory inﬁltrate with
empty osteocytic lacunae (hematoxylin-eosin, original magniﬁcation  10). E, Devitalized trabecular bone with empty lacunae
(short arrows) along with scalloped bony edges pattern (long arrows) (hematoxylin-eosin, original magniﬁcation  100). F,
Surface colony of Actinomyces spp (arrows) (hematoxylin-eosin, original magniﬁcation  40). G, Surface colony of Actino-
myces spp (arrows) is seen together with empty marrow spaces without microorganisms (hematoxylin-eosin, original
magniﬁcation  40).
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Volume 118, Number 4 Franco-Pretto et al. 413literature.4 All patients presented in the present series
were treated with intravenous bisphosphonates and
classiﬁed as having BIONJ stage 3. Radiologic features
of stage 3 BIONJ may not fully explain the pathogen-
esis of BIONJ. However, histopathologic ﬁndings suchas the presence of viable reactive periosteum indicate
that bisphosphonates do not affect osteoblasts in a
direct manner. Because of decreased osteoclastic ac-
tivity, cytokines for endosteal differentiation of pluri-
potential marrow-derived stem cells into bone-forming
Fig. 5. A, Panoramic image reveals generalized sclerotic changes compromising lamina dura of postextraction sockets (ar-
rowheads). B, Devitalized trabecular bone with empty osteocytic lacunae (arrowheads). C, Trabecular bone with empty
osteocytic lacunae (arrows) along with surface colony of Actinomyces spp (arrowheads) (hematoxylin-eosin, original
magniﬁcation  40).
Fig. 4. A, Right maxillary exposed bone with oroantral communication (arrow). B, Panoramic image reveals sclerotic changes
compromising the right posterior maxillary region (short arrow) along with generalized sclerosis compromising lamina dura
(arrows). C, Empty osteocytic lacunae (short arrow), marrow space devoid of inﬂammatory cells or ﬁbrosis. Extensive scalloping
of bone edges suggestive of interrupted Howship lacunae (arrows) (hematoxylin-eosin, original magniﬁcation  40). D, Extended
bone necrosis without inﬂammatory inﬁltrate with empty osteocytic lacunae (arrowheads), acellular marrow space, devoid of
cellular products (hematoxylin-eosin, original magniﬁcation  40).
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are self-renewing and are independent of bone resorp-
tion. This ﬁnding is consistent with those described in
the literature.4
Osteoclasts detached from the bone were also present,
along with nonviable osteoclasts, which conﬁrm the
osteoclastic apoptotic mechanism induced by bisphosph-
onates that has been proposed in other articles.4,5-13
Osteoclastic detachment is increasingly thought tobe a result of the inhibition of posttranslational prenyla-
tion of guanosine triphosphateebinding proteins by
bisphosphonates. Such inhibition results in loss of the
rufﬂed border and altered cytoskeletal organization in
osteoclasts.8,13,14 There were frequent scalloped bone
edges representing empty Howship lacunae, which sug-
gest an interruption of the resorption activity due to
osteoclastic impaired function. This ﬁnding coincides
with those described in the literature.4
OOOO ORIGINAL ARTICLE
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found inﬂammatory inﬁltrate in several parts of the
specimens. Favia et al.,5 using biopsy specimens, found
3 speciﬁc histologic patterns for BIONJ: Areas with
active acute inﬂammation, acellular necrotic sequestra,
and non-necrotic areas without inﬂammation.
The inﬁltrates in this case series were related to su-
perinfection of the exposed bone. Infection is frequently
associated with stage 2 and 3 BIONJ. To ﬁnd BIONJ
histopathology features, it was necessary to perform
analysis in zones without the inﬂammatory inﬁltrates.
This ﬁnding coincides with those observed by Marx
and Tursun.4 They explained that BIONJ physiopa-
thology corresponds to a noninﬂammatory condition
that is the result of a reactive toxicity to bisphospho-
nates, which is different in nature to other conditions
such as osteoradionecrosis (ORN) and suppurative
osteomyelitis (SOM).4
Marx and Tursun4 found common histologic features
between ORN, SOM, and BIONJ: necrotic bone with
empty haversian systems and Volkmann canals. How-
ever, marrow ﬁbrosis is a distinctive histologic feature
in ORN along with nonviable periosteum, consistent
with the hypocellular-hypovascular-hypoxic mecha-
nism involved in this disease. In contrast, histopatho-
logic evidence in this series did show viable
periosteum, which indicates that bisphosphonates are
not directly toxic to osteoblasts but that osteoblasts are
ultimately impaired due to the decreased osteoclastic
function.4 Unlike in BIONJ, there is no osteoclastic
impairment in ORN but rather direct injury to all cells
in the ﬁeld of radiation. The radiation directly damages
the blood supply, the periosteum, the overlying mucosa,
and the overlying skin.
Infection is not considered a part of the primary
mechanism of BIONJ. Microorganisms exhibit an
opportunistic role when the bone becomes exposed.
The bone develops necrosis in the case of BIONJ
because of the inhibitory action of the drug on the
farnesyl synthase enzyme,10-12,15 which results in bone
exposure, and after exposure, the necrotic exposed bone
becomes colonized by microorganisms. In contrast,
histopathologic ﬁndings in SOM specimens suggest
that microorganisms induce an inﬂammatory response
within the marrow space and cause blood vessel
thrombosis as the main mechanism of disease.4 Unlike
in SOM, the microorganisms seen in this series were
found exclusively on the bony surface, supporting the
opportunistic role of microorganisms as described in
the literature.4
The most common isolated microorganisms in cases
of superinfection include Actinomyces spp, Eikenella
spp, and Moraxella spp. Actinomyces spp were isolated
in 3 cases. The administration of clindamycin is not
recommended because of its low effectiveness againstthe microorganisms isolated in BIONJ cases.16 Acti-
nomyces spp are weakly sensitive to clindamycin,
which explains why the drug was not effective in
treating the superinfection in 2 cases.
The current antibiotic therapy recommendation in-
cludes penicillin VK, 500 mg every 6 hours daily, as
empiric treatment and doxycycline, 100 mg daily, as a
second option. Antibiotic therapy should be extended at
least 14 days or until infection signs disappear.16-18
Marx has observed that penicillin VK is well tolerated
for long-term formulation in this group of patients and in
those with bacterial sclerosing osteomyelitis.17 Inter-
estingly, 1 case of this series was refractory to doxycy-
cline treatment and required surgical management.
The mandible is the most affected bone in the
maxillofacial region, at a 2:1 proportion compared with
the maxilla according to several publications.19-21
Zones with anatomic prominences such as torus and
exostoses are predisposed to develop the condition
because of a greater propensity to experience direct
trauma. Other anatomic zones with higher risk include
the internal oblique line and mylohyoid groove.22-25
Other risk factors associated with developing the
condition include dentoalveolar surgical procedures
such as dental extractions and dental implant place-
ment.26-30 Patients with cancer who have periodontal
disease and odontogenic infection have a 7-fold higher
risk to develop BIONJ when treated with intravenous
bisphosphonates.26-28
Previous reports have clearly established other risk
factors associated with the development of BIONJ:
potency of bisphosphonate, drug half-life, dose, route,
and total period of administration.26,29 In the case of
oral bisphosphonates, there is a directly proportional
relation between the severity of the clinical picture and
the period of administration. Because of its low
gastrointestinal absorption, bioavailability ranges be-
tween 0.70% and 0.59%. Thus, it is necessary to
administer bisphosphonates for a long period, which
can result in a total osteoclastic depletion capable of
promoting BIONJ. Previous studies have included pa-
tients who received oral bisphosphonate treatment for
more than 3 years.16
There is no clear correlation between BIONJ severity
and intravenous-route bisphosphonates. When the drug
is administered using the intravenous route, 60% of the
administered drug is absorbed by bone, and the rest is
excreted in urine. This results in a fast depletion of
functional osteoclasts and those precursors located in
the bone marrow.16 In the case of zoledronic acid, the
literature reports a mean of 9.3 months of administra-
tion for the promotion BIONJ, without difference in
case severity between shorter and longer periods of
administration.20 All patients of this case series had a
history of intravenous bisphosphonate therapy. The
ORAL AND MAXILLOFACIAL SURGERY OOOO
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surgical intervention after 12 months of zoledronic acid
intravenous therapy.
Another condition related to increasing severity of
BIONJ cases is the presence of multiple myeloma.
Because of the replacement of the normal bone marrow
cellular population by abnormal cells, the action of
bisphosphonates in this group of patients results in an
earlier and more severe clinical presentation of BIO-
NJ.26 Clinical ﬁndings in the second case in this article
support this conclusion.
The AAOMS developed a BIONJ staging system
that takes into consideration symptoms, imaging ﬁnd-
ings, and the presence of bone exposure.2 The system
has been useful in the diagnosis and management of
this group of patients. However, there is no uniﬁed
method that can aid in establishing the risk of devel-
oping BIONJ.
Marx et al.,16 in a series of 30 patients with BIONJ,
found a correlation between serum levels of CTX
(c-terminal-telopeptide) and occurrence of the disease.
The CTX test measures concentration of crossed pep-
tide links that result from collagen type I degradation
during bone reabsorption. Flichy-Fernández et al.31 did
not ﬁnd signiﬁcant differences between CTX values
and doses and periods of administration of oral
bisphosphonates.
Although the present series included 5 cases, the
relevant histopathologic features described herein,
along with the effects of bisphosphonates on bone
metabolism, may explain the physiopathology of this
disease, which is different from other necrotizing and
inﬂammatory conditions such as ORN and SOM. It is
important that every patient undergoing bisphosphonate
treatment is previously submitted for oral examination
to treat all dental needs before beginning bisphospho-
nate therapy.
CONCLUSION
Further study with larger series should be accomplished
to completely understand the pathophysiology of the
disease. Future research should focus on histopatho-
logic differences between BIONJ, SOM, and ORN that
could conﬁrm separate mechanisms for each disease, to
improve prevention and treatment protocols based on
current evidence.
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